

17 November 2022

ASX Announcement

Results of Annual General Meeting

MELBOURNE Australia, 17 November 2022: Australian mid-clinical stage antiviral drug repurposing company, Island Pharmaceuticals Ltd (ASX: ILA) advises that its Annual General Meeting was held today at 11.30 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Approved for release to the ASX by:

Dr Paul
MacLeman
Executive
Chairman Island
Pharmaceuticals
Ltd

info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

Disclosure of Proxy Votes

Island Pharmaceuticals Limited

Annual General Meeting

Thursday, 17 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	15,478,015	12,874,207 83.18%	2,593,808 16.76%	0	10,000 0.06%	12,884,207 83.24%	2,593,808 16.76%	0
2 Re-election of Anna Lavelle	P	31,734,839	29,791,892 93.88%	1,832,947 5.78%	25,913	110,000 0.35%	29,901,892 94.22%	1,832,947 5.78%	25,913
3 Re-election of Albert Hansen	P	31,734,839	29,131,031 91.80%	2,493,808 7.86%	25,913	110,000 0.35%	29,241,031 92.14%	2,493,808 7.86%	25,913
4 Approval of increased placement capacity	P	31,760,752	29,026,391 91.39%	2,619,721 8.25%	0	114,640 0.36%	29,141,031 91.75%	2,619,721 8.25%	0

